Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.
Publication/Presentation Date
3-1-2010
Abstract
Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.
Volume
76
Issue
3 Suppl
First Page
145
Last Page
150
ISSN
1879-355X
Published In/Presented At
Bentzen, S. M., Parliament, M., Deasy, J. O., Dicker, A., Curran, W. J., Williams, J. P., & Rosenstein, B. S. (2010). Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. International journal of radiation oncology, biology, physics, 76(3 Suppl), S145–S150. https://doi.org/10.1016/j.ijrobp.2009.08.076
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
20171510
Department(s)
Administration and Leadership
Document Type
Article